Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.
Vaccine. 2011 Jul 12; 29(31):4963-72.V

Abstract

OBJECTIVE

Since the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) were recently licensed for use in Argentina, both vaccines were evaluated to estimate the costs, health benefits and cost-effectiveness of adding a PCV to the routine child immunization schedule.

METHODOLOGY

The integrated TRIVAC vaccine cost-effectiveness model from Pan American Health Organization's ProVac Initiative (Version 1.0.65) was used to assess the health outcomes of 20 successive cohorts from birth to 5 years of age. PCV-10 and PCV-13 were each compared to a scenario assuming no PCV vaccination. A 3+1 (three doses+booster) schedule and a vaccination price of US$ 20.75 per dose was assumed in the base case for both vaccines.

RESULTS

Introduction of PCV-13 rather than PCV-10 would increase the number of life years gained (LYG) by at least 10%. The number of LYG (and LYG after adjustment for DALY morbidity weights) was 56,882 (64,252) for PCV-10 compared to 65,038 (71,628) for PCV-13. From the health system perspective, the cost per DALY averted was US$ 8973 and US$ 10,948 for PCV-10 and PCV-13 respectively, and US$ 8546 and US$ 10,510 respectively, after incorporating costs saved by households. When PCV13 was compared to PCV10 directly, the additional benefits of PCV-13 was conferred at a cost of US$ 28,147 per DALY averted. Cost-effectiveness was influenced mainly by vaccine price, serotype replacement, pneumonia mortality and discount rate.

CONCLUSION

Routine vaccination against S. pneumoniae in Argentina would be cost-effective with either PCV-10 or PCV-13. PCV-13, with higher coverage of local serotypes, would prevent more cases of pneumonia, invasive pneumococcal disease, sequelae and deaths with a higher number of LYG and DALYs averted, but PCV-10, due its higher impact in the prevention of AOM, would save more costs to the healthcare system.

Authors+Show Affiliations

Ministerio de Salud de la Nación, Argentina. anauru@yahoo.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21621575

Citation

Urueña, Analía, et al. "Cost-effectiveness Analysis of the 10- and 13-valent Pneumococcal Conjugate Vaccines in Argentina." Vaccine, vol. 29, no. 31, 2011, pp. 4963-72.
Urueña A, Pippo T, Betelu MS, et al. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine. 2011;29(31):4963-72.
Urueña, A., Pippo, T., Betelu, M. S., Virgilio, F., Giglio, N., Gentile, A., Jimenez, S. G., Jáuregui, B., Clark, A. D., Diosque, M., & Vizzotti, C. (2011). Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine, 29(31), 4963-72. https://doi.org/10.1016/j.vaccine.2011.04.111
Urueña A, et al. Cost-effectiveness Analysis of the 10- and 13-valent Pneumococcal Conjugate Vaccines in Argentina. Vaccine. 2011 Jul 12;29(31):4963-72. PubMed PMID: 21621575.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. AU - Urueña,Analía, AU - Pippo,Tomás, AU - Betelu,María Sol, AU - Virgilio,Federico, AU - Giglio,Norberto, AU - Gentile,Angela, AU - Jimenez,Salvador García, AU - Jáuregui,Bárbara, AU - Clark,Andrew D, AU - Diosque,Máximo, AU - Vizzotti,Carla, Y1 - 2011/05/27/ PY - 2011/02/25/received PY - 2011/04/20/revised PY - 2011/04/27/accepted PY - 2011/5/31/entrez PY - 2011/5/31/pubmed PY - 2011/10/19/medline SP - 4963 EP - 72 JF - Vaccine JO - Vaccine VL - 29 IS - 31 N2 - OBJECTIVE: Since the 10-valent pneumococcal conjugate vaccine (PCV-10) and 13-valent pneumococcal conjugate vaccine (PCV-13) were recently licensed for use in Argentina, both vaccines were evaluated to estimate the costs, health benefits and cost-effectiveness of adding a PCV to the routine child immunization schedule. METHODOLOGY: The integrated TRIVAC vaccine cost-effectiveness model from Pan American Health Organization's ProVac Initiative (Version 1.0.65) was used to assess the health outcomes of 20 successive cohorts from birth to 5 years of age. PCV-10 and PCV-13 were each compared to a scenario assuming no PCV vaccination. A 3+1 (three doses+booster) schedule and a vaccination price of US$ 20.75 per dose was assumed in the base case for both vaccines. RESULTS: Introduction of PCV-13 rather than PCV-10 would increase the number of life years gained (LYG) by at least 10%. The number of LYG (and LYG after adjustment for DALY morbidity weights) was 56,882 (64,252) for PCV-10 compared to 65,038 (71,628) for PCV-13. From the health system perspective, the cost per DALY averted was US$ 8973 and US$ 10,948 for PCV-10 and PCV-13 respectively, and US$ 8546 and US$ 10,510 respectively, after incorporating costs saved by households. When PCV13 was compared to PCV10 directly, the additional benefits of PCV-13 was conferred at a cost of US$ 28,147 per DALY averted. Cost-effectiveness was influenced mainly by vaccine price, serotype replacement, pneumonia mortality and discount rate. CONCLUSION: Routine vaccination against S. pneumoniae in Argentina would be cost-effective with either PCV-10 or PCV-13. PCV-13, with higher coverage of local serotypes, would prevent more cases of pneumonia, invasive pneumococcal disease, sequelae and deaths with a higher number of LYG and DALYs averted, but PCV-10, due its higher impact in the prevention of AOM, would save more costs to the healthcare system. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/21621575/Cost_effectiveness_analysis_of_the_10__and_13_valent_pneumococcal_conjugate_vaccines_in_Argentina_ DB - PRIME DP - Unbound Medicine ER -